EGFR and non-small cell lung carcinoma: For example, Hu et al. [31] found in 99 NSCLC patients with EGFR-TKI resistance that immunochemotherapy was significantly more effective than ICI monotherapy (median PFS: 5.0 vs. 3.0 months, P = 0.02; median OS: 19.0 vs. 7.4 months, P = 0.009).